Uncompensated autoantibody-mediated red blood cell (RBC) consumption is the hallmark
of autoimmune hemolytic anemia (AIHA). Classification of AIHA is pathophysiologically …

Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disease that affects 1 to
3/100 000 patients per year. AIHA caused by warm autoantibodies (w-AIHA), ie, antibodies …

The independent genomic inheritance of the human leukocyte antigen (HLA) and the ABO-
blood group system allows for HLA-matched hematopoietic progenitor cell transplantation …

The direct antiglobulin test (DAT; sometimes referred to as the “Coombs” test) continues to
be one of the most widely used assays in laboratory medicine. First described about 70 …

Autoimmune hemolytic anemia (AIHA) is defined by increased erythrocyte turnover
mediated by autoimmune mechanisms. While corticosteroids remain first-line therapy in …

Background Patients with malignancy comprise a unique group for whom transfusions play
an important role. Because the need for transfusions may span a long period of time, these …

In this report, we will review the various clinical and laboratory approaches to diagnosing
immune thrombocytopenia (ITP), with a focus on its laboratory diagnosis. We will also …

The diagnosis of ABO hemolytic disease of the newborn (ABO HDN) has been the subject of
considerable debate and clinical confusion. Its use as an overarching default diagnosis for …

The recommendations published in 20061 have been revised in the light of current scientific
evidence: the immunohaematological and instrumental investigations that should be …

Autoimmune hemolytic anemia (AIHA) is defined as the destruction of circulating red blood
cells (RBCs) in the setting of anti-RBC autoantibodies. 1 The in vivo and in vitro behavior of …